GSK (GSK) announced that the European Medicines Agency, EMA, has granted Priority Medicines, PRIME, Designation for GSK5764227, its B7-H3-targeted antibody-drug conjugate, ADC, being evaluated for the treatment of patients with relapsed extensive-stage small-cell lung cancer, ES-SCLC. The PRIME Designation supports the development of medicines with potential to offer a major therapeutic advantage for patients. This is the second regulatory designation for GSK’227, following the US Food and Drug Administration’s decision to grant Breakthrough Therapy Designation in August 2024.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK announces FDA granted BTD for Jemperli
- Relation announces two strategic collaborations with GSK
- GSK says median overall survival not reached in multiple myeloma study
- GSK announces NMPA of China accepted review of NDA for Blenrep
- GSK announces U.S. FDA accepted its submission for use of Nucala in COPD